This is the phase I study to evaluate the pharmacokinetics and safety of DA-2811 and Forxiga® after a single oral dose in healthy volunteers.

The study will also compare the pharmacokinetics and safety profiles of DA-2811 under fasting and fed states in healthy subjects.

Inclusion Criteria:

• Healthy male and/or female subjects
• BMI between 18.5 and 29.9 kg/m2 and weigh at least 50 kg
• Volunteer who totally understands the progress of this clinical trial, make decision by his or her free will, and signed a consent form to follow the progress.

Exclusion Criteria:

• Volunteer who has present or past history of clinically significant cardiovascular, respiratory, urinary, gastrointestinal, hepatic, renal, skin, immunological, musculoskeletal, endocrinal, neurological, psychiatric and/or hematological disease
• Vulnerable to dehydration due to poor oral intake or clinically significant dehydration as judged by the investigator
• History of gastrointestinal disease or any gastrointestinal surgery(except for simple appendectomy, hernia surgery, hemorrhoid surgery)
• History of diseases that may impact absorption, distribution, metabolism, and excretion of the study drugs.
• Hypersensitivity to a drug containing an ingredient of the investigational product, Sodium glucose transporter-2 inhibitors, additional ingredient or other drugs (e.g., aspirin, antibiotics, etc.) or medical history of clinically significant hypersensitivity.
• History of clinically significant active chronic disease
• volunteer who has genetic disorder like lapp lactase deficiency or glucose-galactose malabsorption.
• History of clinically significant allergies including drug allergies
• History of drug abuse or addicted
• Clinical laboratory test values are outside the accepted normal range
• Participation in another clinical trial within 6 months of the first IP administration
• Sexually active women of childbearing potential not consistently and correctly practicing birth control by dual contraceptive method until 2 months after last IP administration
• Breast-feeding period, pregnant, or positive to urine pregnancy test (conducted before the first drug administration)
• Subjects considered as unsuitable based on medical judgement by investigators